Identification of Novel Adjuvants for Ebola Virus-Like Particle Vaccine

Feng, Huapeng; Nakatsu, Sumiho; Lopes, Tiago José da Silva; Imai, Masaki; Yamayoshi, Seiya; Yamashita, Makoto; Watanabe, Tokiko; Kawaoka, Yoshihiro

doi:10.3390/vaccines8020215

Cited by 3 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chimpanzee adenovirus type 7 with a heterologous boost protected mice long-term 42 , as did rVSV-ZEBOV in which mice maintained high GP-specific IgG 43 . Adjuvant studies in mice have involved the VLP vaccine strategy 44 – 48 , including long-term protection by VLPs adjuvanted with GLA-SE 49 . Prompted by the 2014–2016 West African outbreak, research in NHPs and clinical trials was accelerated 50 , and several platforms have displayed longevity in NHPs 24 , 51 , 52 .…”

Section: Discussionmentioning

confidence: 99%

Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge

et al. 2023

View full text Add to dashboard Cite

Ebola virus is the primary contributor to the global threat of filovirus severe hemorrhagic fever, and Ebola virus disease has a case fatality rate of 50–90%. An inactivated, bivalent filovirus/rabies virus vaccine, FILORAB1, consists of recombinant rabies virus virions expressing the Ebola virus glycoprotein. FILORAB1 is immunogenic and protective from Ebola virus challenge in mice and non-human primates, and protection is enhanced when formulated with toll-like receptor 4 agonist Glucopyranosyl lipid adjuvant (GLA) in a squalene oil-in-water emulsion (SE). Through an adjuvant comparison in mice, we demonstrate that GLA-SE improves FILORAB1 efficacy by activating the innate immune system and shaping a Th1-biased adaptive immune response. GLA-SE adjuvanted mice and those adjuvanted with the SE component are better protected from surrogate challenge, while Th2 alum adjuvanted mice are not. Additionally, the immune response to FILORAB1 is long-lasting, as exhibited by highly-maintained serum antibody titers and long-lived cells in the spleen and bone marrow.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge

et al. 2023

View full text Add to dashboard Cite

show abstract

Epitope-based peptide vaccine against Bombali Ebolavirus viral protein 40: An immunoinformatics combined with molecular docking studies

Mustafa

Shantier

Abdelmageed

et al. 2021

Informatics in Medicine Unlocked

View full text Add to dashboard Cite

Epitope-Based Peptide Vaccine against Bombali Ebolavirus Viral Protein 40: An Immunoinformatics Combined with Molecular Docking Studies

Mustafa

Shantier

Abdelmageed

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundBombali Ebolavirus is RNA viruses belong to the Filoviridae family. They are causing lethal hemorrhagic fever with high mortality rate. Despite having available molecular knowledge of this virus, no approved vaccine or antiviral drugs have been developed yet for the eradication of Bombali Ebolavirus infections in humans.Objectivethe present study described a multi epitope-based peptide vaccine against Bombali Ebolavirus matrix protein VP40, using several immunoinformatics tools.Materials and MethodsThe six strains of Ebolavirus were retrieved from NCBI and Uniprot databases and submitted to VaxiJen to identify the most antigenic protein among all. Then PSIPRED, SOPMA, QMEAN, and PROCHECK tools were used to check the protein quality. T-cell prediction, population coverage, and molecular docking analysis were achieved to select peptides containing multiple Bombali VP40 epitopes showing interaction with multiple HLA molecules for expected immune response across the world.ResultBombali Ebola (YP_009513276.1) was found to be the most antigenic protein among all. Which it has been used in all required analysis. For T cell three epitopes showed high affinity to MHC class I (YSFDSTTAA, VQLPQYFTF, and MVNVISGPK) and high population coverage against Africa and the world. Furthermore in MHC class II, six promising epitopes that associated with most common MHC class II alleles.ConclusionThe above result conclude that, these peptides capable of provoking T-cell response and being interacted with a wide range of HLA molecules have a strong potential to be a vaccine against Bombali Ebolavirus.

show abstract

Identification of Novel Adjuvants for Ebola Virus-Like Particle Vaccine

Cited by 3 publications

References 52 publications

Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge

Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge

Epitope-based peptide vaccine against Bombali Ebolavirus viral protein 40: An immunoinformatics combined with molecular docking studies

Epitope-Based Peptide Vaccine against Bombali Ebolavirus Viral Protein 40: An Immunoinformatics Combined with Molecular Docking Studies

Contact Info

Product

Resources

About